New data in pancreatic #cancer!
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
May 28, 2025 at 7:06 AM
New data in pancreatic #cancer!
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
New research shows that flexible trial design is key to addressing #FinancialToxicity in #CancerCare. The CREDIT study boosted enrollment 3x by dropping strict caregiver requirements, paving the way for real-world financial navigation programs.
#OncoResearch #ImplementationScience #HealthEquity
#OncoResearch #ImplementationScience #HealthEquity
May 21, 2025 at 5:45 PM
New research shows that flexible trial design is key to addressing #FinancialToxicity in #CancerCare. The CREDIT study boosted enrollment 3x by dropping strict caregiver requirements, paving the way for real-world financial navigation programs.
#OncoResearch #ImplementationScience #HealthEquity
#OncoResearch #ImplementationScience #HealthEquity
Miércoles de citometria de flujo ✌️ #science #oncoresearch
December 11, 2024 at 1:04 PM
Miércoles de citometria de flujo ✌️ #science #oncoresearch
